Prophylactic Vaccination of Cancer Patients and Hematopoietic Stem Cell Transplant Recipients

摘要: Prophylactic immunization in cancer patients is safe and cost-effective reducing the disease burden complications arising from vaccine preventable infections. For maximal effectiveness, should be vaccinated with inactivated vaccines at least 2 weeks prior or 3 months subsequent to myeloablative chemotherapy. Hematopoietic stem cell transplant recipients similarly 6–12 posttransplant, immune reconstitution permitting. Vaccination of B-cell malignancies more problematic, but difficulties can somewhat ameliorated by applying higher doses greater frequencies than would typical for immunocompetent individuals. Live are typically considered unsafe oncology patients, may safely administered HSCT who >2 years posttransplant. While many common infections managed through a strategy conscientious vaccination, there other serious that specifically afflict immunocompromised patient populations which effective do not yet exist. will address some these infectious conditions currently development, it unlikely all important oncological ultimately addressed approach as market-based development strategies target negligible impact upon populations. In this chapter, we present comprehensive review vaccination patients.